Corrie's Shared Resources

Liver Biopsy Evaluation in MASH
During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...

Advancements in MASLD Diagnosis: Non-Invasive Tools
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NASH, is a growing health concern due to its association with...

GLP-1 Agonists’ Potential for Fibrosis Regression
In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating...

Detecting Significant Fibrosis in Hispanic Patients With MASLD
A recent study evaluated the performance of noninvasive tests (NITs) for detecting significant fibrosis in Hispanic patients with metabolic dysfunction–associated...

Resmetirom and Advanced Liver Fibrosis
Resmetirom (MGL-3196) received accelerated FDA approval in March 2024 for treating MASH with moderate to advanced liver fibrosis (F2-F3). This...

Resmetirom FDA-Approved for MASH
In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...